| Company Name: | Alpharma Inc. | | Ticker Symbol: | ALO | | | WWW Address: | www.alpharma.com |
| CEO: | Dean J. Mitchell | | No. of Employees: | 2,000 |
| Common Issue Type: | CS | | Business Description: | A pharmaceutical company that develops, manufactures and markets pharmaceutical products for humans and animals. The Company's businesses are organized in three segments; Pharmaceuticals, Active Pharmaceutical Ingredients and Animal Health.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 11.69 |  0.0 | - | - | | 36.95 | 36.94 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 489.6 | 41.9 | 0.48 | -0.32 | 0.00 | 13.9 | 0.0 | 38.14 - 17.55 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 36.94 | $ | | PE Ratio - LTM | 13.9 | |
| Market Capitalisation | 489.6 | mil |
| Latest Shares Outstanding | 41.9 | mil |
| Earnings pS (EPS) | -0.32 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 361,213 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 41.4 | mil |
| Float as % of Shares Outstanding | 98.9 | % |
| Foreign Sales | 205 | mil |
| Domestic Sales | 517 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 50.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 23.80 | % |
| Gross Profit Margin | 67.7 | % |
| EBITDA Margin | -6.7 | % |
| Pre-Tax Profit Margin | -12.2 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | 8.4 | % |
| Return on Equity (ROE) | 14.6 | % |
| Return on Capital Invested (ROCI) | 10.5 | % |
| Current Ratio | 4.5 | |
| Leverage Ratio (Assets/Equity) | 1.7 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.39 | |
| LT Debt/Total Capital | 28.0 | % |
| Working Capital pS | 15.27 | $ |
| Cash pS | 13.63 | $ |
| Book-Value pS | 18.73 | $ |
| Tangible Book-Value pS | 10.74 | $ |
| Cash Flow pS | 3.79 | $ |
| Free Cash Flow pS | 6.96 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.97 | |
| Price/Tangible Book Ratio | 3.44 | |
| Price/Cash Flow | 9.7 | |
| Price/Free Cash Flow | 5.3 | |
| P/E as % of Industry Group | 140.0 | % |
| P/E as % of Sector Segment | 60.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.7 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.1 | 97 | 4,050 | 10 |
| 4 Weeks | 36.99 | 34.37 | 35.84 | 3.1 | 100 | 6,119 | 104,023 |
| 13 Weeks | 36.99 | 26.10 | 34.86 | 6.0 | 129 | 10,884 | 663,937 |
| 26 Weeks | 38.14 | 21.27 | 22.77 | 62.2 | 227 | 13,745 | 1,718,088 |
| 52 Weeks | 38.14 | 17.55 | 19.42 | 90.2 | 297 | 11,336 | 2,833,983 |
| YTD | 38.14 | 17.55 | - | 83.3 | 298 | 11,247 | 2,845,414 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 36.80 | 36.45 | 33.75 | 30.16 | 29.28 | 0.48 | 0.35 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -13.21 | 50.6 | -1.72 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -40.21 | NA | -33.55 |
| R&D | 17.27 | NA | 64.93 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -4.4 | -0.1 | 10.5 |
| Earnings % | 319.1 | -72.6 | -100.0 |
| EPS % | 329.3 | -70.6 | -100.0 |
| EPS $ | 3.03 | -0.24 | -1.84 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 29.74 |
| Current Ratio | 2.9 |
| Quick Ratio (Acid Test) | 2.2 |
| Liquidity Ratio (Cash) | 1.53 |
| Receivables Turnover | 6.1 |
| Average Collection Period | 59 |
| Working Capital/Equity | 52.4 |
| Working Capital pS | 8.75 |
| Cash-Flow pS | 0.98 |
| Free Cash-Flow pS | -2.79 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.65 |
| Financial Leverage Ratio (Assets/Equity) | 1.8 |
| Debt Ratio | 43.2 |
| Total Debt/Equity (Gearing Ratio) | 0.43 |
| LT Debt/Equity | 0.41 |
| LT Debt/Capital Invested | 34.8 |
| LT Debt/Total Liabilities | 53.9 |
| Interest Cover | 2.8 |
| Interest/Capital Invested | 0.48 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.09 |
| Tobin's Q Ratio | 1.20 |
| Current P/E Ratio - LTM | 13.90 |
| Enterprise Value (EV)/EBITDA | 34.13 |
| Enterprise Value (EV)/Free Cash Flow | -16.10 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.44 |
| Price/Book Ratio - LTM | 1.97 |
| Price/Cash Flow Ratio | 9.7 |
| Price/Free Cash Flow Ratio - LTM | 5.3 |
| Price/Sales Ratio | 2.21 |
| P/E Ratio (1 month ago) - LTM | 13.6 |
| P/E Ratio (26 weeks ago) - LTM | 6.8 |
| P/E Ratio (52 weeks ago) - LTM | 16.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 140.0 |
| P/E as % of Sector Segment | 60.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 6.85 |
| Current Liabilities pS | 4.53 |
| Tangible Book Value pS - LTM | 10.74 |
| Book Value pS - LTM | 18.73 |
| Capital Invested pS | 24.62 |
| Cash pS - LTM | 13.63 |
| Cash Flow pS - LTM | 3.79 |
| Free Cash Flow pS - LTM | 6.96 |
| Earnings pS (EPS) | -0.32 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -16.91 |
| Free Cash Flow Margin 5YEAR AVG | 7.85 |
| Net Profit Margin | -1.9 |
| Net Profit Margin - 5YEAR AVRG. | -2.1 |
| Equity Productivity | 0.99 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.70 |
| Return on Capital Invested (ROCI) | -1.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -1.6 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | -1.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | -1.2 |
| Gross Profit Margin | 67.7 |
| Gross Profit Margin - 5YEAR AVRG. | 56.5 |
| EBITDA Margin - LTM | -6.7 |
| EBIT Margin - LTM | -11.9 |
| Pre-Tax Profit Margin | 1.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -1.8 |
| Effective Tax Rate | 245.2 |
| Effective Tax Rate - 5YEAR AVRG. | 44.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 228 |
| Revenue per Employee | 361,213 |
| Net Income per Employee | -6,791 |
| Average Collection Period | 65 |
| Receivables Turnover | 6.1 |
| Day's Inventory Turnover Ratio | 163 |
| Inventory Turnover | 2.2 |
| Inventory/Sales | 17.4 |
| Accounts Payble/Sales | 8.02 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 1.89 |
| Fixed Assets Turnover | 1.02 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 2.39 |
| Revenue per $ Plant | 2.55 |
| Revenue per $ Common Equity | 0.99 |
| Revenue per $ Capital Invested | 0.70 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 37.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 32.1 |
| Research & Devlopment (R&D) as % of Revenue | 19.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 19.4 |
|
|  
|
| |
 |  |
